Get the Stockscreener App
2.89
3.96%
+0.11
Bullfrog AI Holdings Inc stock is currently priced at $2.89, with a 24-hour trading volume of 59,003.
It has seen a +3.96% increased in the last 24 hours and a -7.96% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.75 pivot point. If it approaches the $2.90 resistance level, significant changes may occur.
Previous Close:
$2.78
Open:
$2.74
24h Volume:
59,003
Market Cap:
$22.69M
Revenue:
-
Net Income/Loss:
$-5.36M
P/E Ratio:
-3.765
EPS:
-0.7676
Net Cash Flow:
$-6.00M
1W Performance:
-3.02%
1M Performance:
-7.96%
6M Performance:
+1.05%
1Y Performance:
-40.41%
1D Range:
$2.74
$2.89
52W Range:
$2.36
$8.35
Bullfrog AI Holdings Inc Stock (BFRG) Company Profile
Name
Bullfrog AI Holdings Inc
Sector
Industry
Phone
240 658 6710
Address
325 Ellington Blvd, Unit 317, Gaithersburg
Bullfrog AI Holdings Inc Stock (BFRG) Latest News
Ratio Examination: Bullfrog AI Holdings Inc (BFRG)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
The Dwinnex
Insiders Sold Bullfrog AI Holdings Prematurely At US$3.83 With Stock Trading Higher - Simply Wall St
Simply Wall St
Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on June 12
GlobeNewswire Inc.
BullFrog AI Holdings Releases Key Investor Insights - TipRanks.com - TipRanks
TipRanks
BullFrog AI and Lieber Institute for Brain Development Collaboration Identifies Novel Drug Targets for Neuropsychiatric ... - WICZ
WICZ
Bullfrog AI Holdings, Inc. and Lieber Institute for Brain Development Collaboration Identifies Novel Drug Targets for ... - Marketscreener.com
Marketscreener.com
Bullfrog AI Holdings Inc Stock (BFRG) Financials Data
Bullfrog AI Holdings Inc (BFRG) Net Income 2024
BFRG net income (TTM) was -$5.36 million for the quarter ending December 31, 2023, a -91.11% decrease year-over-year.
Bullfrog AI Holdings Inc (BFRG) Cash Flow 2024
BFRG recorded a free cash flow (TTM) of -$6.00 million for the quarter ending December 31, 2023, a -558.83% decrease year-over-year.
Bullfrog AI Holdings Inc (BFRG) Earnings per Share 2024
BFRG earnings per share (TTM) was -$0.89 for the quarter ending December 31, 2023, a -76.80% decline year-over-year.
Bullfrog AI Holdings Inc Stock (BFRG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Singh Vininder | Chief Executive Officer |
Apr 01 '24 |
Sale |
2.99 |
43,056 |
128,647 |
2,549,390 |
| Singh Vininder | Chief Executive Officer |
Jan 22 '24 |
Sale |
7.50 |
25,000 |
187,500 |
2,597,294 |
| Singh Vininder | Chief Executive Officer |
Jan 17 '24 |
Sale |
3.18 |
4,848 |
15,440 |
2,642,446 |
| Singh Vininder | Chief Executive Officer |
Jan 16 '24 |
Sale |
2.55 |
8,516 |
21,741 |
2,647,294 |
| Singh Vininder | Chief Executive Officer |
Jan 12 '24 |
Sale |
2.56 |
1,515 |
3,873 |
2,655,810 |
| Singh Vininder | Chief Executive Officer |
Jan 11 '24 |
Sale |
2.58 |
5,660 |
14,613 |
2,657,325 |
| Singh Vininder | Chief Executive Officer |
Jan 10 '24 |
Sale |
2.75 |
4,780 |
13,156 |
2,662,985 |
| Singh Vininder | Chief Executive Officer |
Jan 09 '24 |
Sale |
2.82 |
3,144 |
8,859 |
2,667,765 |
| Singh Vininder | Chief Executive Officer |
Jan 08 '24 |
Sale |
2.88 |
5,184 |
14,925 |
2,670,909 |
| Singh Vininder | Chief Executive Officer |
Jan 05 '24 |
Sale |
2.90 |
2,644 |
7,662 |
2,676,093 |
About Bullfrog AI Holdings Inc
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
1.24%
0.07%
Cap:
|
Volume (24h):